The in vitro effects of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR, fenretinide) on primary B-cell chronic lymphocytic leukemia (CLL) cells from previously untreated CLL patients were investigated. 4HPR promoted the intrinsic apoptotic pathway by reactive oxygen species (ROS) generation and was accompanied by drop of Mcl-1 protein expression. The latter was not attributable to transcriptional downregulation but to protein degradation mediated by jun N-terminal kinase activation, and likely by NF-kB downregulation and Noxa upregulation. CLL cells stimulated in vitro with CD40L did not increase 4HPR chemoresistance if activation was accompanied by proliferation. Intra-patient analysis confirmed that the proliferating pool of CLL cells was more sensitive to the cytotoxic action of 4HPR than the activated but resting CLL subpopulation. The different 4HPR susceptibility of the two subpopulations was associated with higher Noxa expression in proliferating CLLs. Combination experiments revealed that 4HPR strongly potentiated ABT-737 cytotoxicity, especially in proliferating CLL cells that displayed amplified chemoresistance to ABT-737 alone. Synergic cytotoxicity was also demonstrated in combination with fludarabine, in both resting and stimulated CLL samples. This study entitles 4HPR to be assayed as a chemotherapeutic adjuvant for the treatment of CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a dynamic disease arising from unbalanced homeostasis of birthing and dying leukemic cells. Within lymphoid tissues, CLL cells receive activation and proliferation stimuli from the microenvironment before being released into the peripheral blood, where they undergo accumulation, as apoptosis does not counterbalance previous proliferation. [1] [2] [3] Drugs that are both cytotoxic on cycling CLL cells and able to affect CLLs' apoptosis resistance would be greatly beneficial in the treatment of this disease.
The Bcl-2 family participates in preserving CLL cell death resistance. CLL cells display increased levels of antiapoptotic Bcl-2 family members, particularly CLL cells from lymph nodes, 4 from patients resistant to chemotherapy 5 or subjected in vitro to microenvironment stimuli. 6 Especially relevant is Mcl-1, for which elevated levels are associated with poor treatment response and high risk of CLL disease progression. 7, 8 Mcl-1 reduction strategies were able to restore in vitro chemotherapic cytotoxicity. 6, 9 CLL cells are sensitive to oxidative stress. They lose viability when incubated with H 2 O 2 -generating systems 10 and display compromised antioxidant defense. 11, 12 N-(4-hydroxyphenyl)retinamide (4HPR, fenretinide) is a synthetic retinoid with chemopreventive/cytotoxic activity against various cancers. [13] [14] [15] [16] [17] 4HPR was shown to induce apoptosis in solid and hematologic tumor cells through reactive oxygen species (ROS) generation [18] [19] [20] [21] and Bcl-2/Mcl-1 decrease. 18, 22 No studies have examined the activity of 4HPR on CLL cells.
We investigated the in vitro effects of 4HPR on primary leukemic cells from CLL patients, under resting or activated conditions, and its cytotoxicity combined with one classical CLL chemotherapeutic drug and one BH3-only mimetic.
MATERIALS AND METHODS

CLL cells and drugs
CLL cells were obtained from the peripheral blood of CLL patients as previously described, 23 after informed consent according to the Declaration of Helsinki. In vitro activation of CLL cells by CD40L-NIH 3T3 cells and drug treatments are described in Supplementary Materials and methods.
Generation of ROS was assessed by conversion of hydroethidine to ethidium bromide. When hydroethidine reacts with oxygen-derived free radicals produced inside the cells, it is transformed into the fluorescent compound ethidium bromide. CLL cells were incubated with 10 mM hydroethidine (10 min, 37 1C) and ethidium bromide fluorescence analyzed by flow cytometry.
Annexin V assays and use of caspase inhibitor DEVD-FMK (either FITC conjugated for intracellular active-caspase detection or non-fluorescent for inhibiting caspase activation during cell cultures) are described in Supplementary Materials and methods.
RNA and protein expression
In Supplementary Materials and methods, qRT-PCR and analysis of protein expression (KI67, Bcl-2 proteins and phosphorylated kinases) by western blots and/or flow-cytometric intracellular immunofluorescence are described.
Combination cytotoxicity
Cytotoxicity of 4HPR administered together with fludarabine (F-ara-AMP) or ABT-737 was calculated by the Chou-Talalay method 24 with the CalcuSyn software (Biosoft, Cambridge, UK). Combination index (CI), computed from dose-effect curves of drugs alone and in combination, represents a measure of the effect of drug interaction (additive effect: 0.9oCIo1.1, synergism: CIo0.9 and antagonism: CI41.1). CI depends on the 'fractional effect level' at which it is calculated. We considered two levels of cytotoxicity, LC 75 and LC 90 (concentration lethal to 75% and 90% of CLL cells). In 4HPR-fludarabine combination tests, the two drugs were added at constant molar ratios of 1:1. ABT-737 alone is effective already in the nanomolar range. Thus, 4HPR:ABT-737 ratios were 1000:1 for resting CLL samples and 100:1 for CD40L-stimulated samples (as activation augmented ABT-737 chemoresistance).
Dose reduction index (DRI), calculated from cytotoxicity profiles of drugs alone and in combination, indicates how many times F-ara-AMP or ABT-737 doses can be reduced, when used in combination with a coordinated dose of 4HPR, to reach a given cytotoxicity.
Statistical analysis
The statistical significance of differences before and after treatments was evaluated by Wilcoxon signed-rank test, and the significance of the difference between CLL patient subgroups by Mann-Whitney U-tests. SPSS (Chicago, IL, USA) and GraphPad Prism software (San Diego, CA, USA) were used. P-values were considered significant at Pp0.05.
Data in figures are mean values from two or three experiments±half-range (in case of two independent experiments) or s.d. (in case of three experiments). When error bars are not displayed for figure clarity reasons, half-range and s.d. did not exceed 15% of the mean.
Figure notations: *Po0.05; **Po0.01; ***Po0.001; n.s., not significant.
RESULTS
4HPR induces apoptosis of CLL cells through ROS generation
In vitro cytotoxicity of 4HPR was first tested on eight CLL samples ( Figure 1a ) by flow-cytometric PI-uptake tests. Average LC 50 at 48 h treatment time was slightly below 10 mM. Thus, this concentration was chosen for almost all subsequent experiments. Viability assays were extended to 30 samples from previously untreated CLL patients, which confirmed that 4HPR induced Figure S1) . CLLs cultured in whole autologous serum or human AB serum became slightly less chemosensitive (Supplemenatary Figure S2 ), but still retained remarkable cytotoxicity at 20 mM (Supplementary Figure S2) , which is a concentration achievable in vivo and well tolerated. [25] [26] [27] We examined how 4HPR induced apoptosis of CLL cells. DNA flow cytometry revealed that 4HPR induced DNA fragmentation, as demonstrated by the appearance of cells with sub-G 0 /G 1 DNA content (Figure 1c) , and that caspases were involved in this process, as the fraction of sub-G 0 /G 1 cells was substantially reduced by caspase3 inhibitor (Figure 1c We were interested in protein changes occurring before overt cellular death. To this end, we selectively analyzed a CLL subpopulation based on its flow-cytometric light-scatter characteristics of 'high FSC/low SSC' (called herein the 'live' gate), as these cells have still intact DC, intact plasma membrane and no activated caspase 3. These are cells, within 4HPR cultures, Abbreviations: 4HPR, N-(4-hydroxyphenyl)retinamide; CLL, chronic lymphocytic leukemia.
a Rearranged IGHV-D-J segments were sequenced from cDNA and analyzed as described Supplementary Materials and methods. The CLL patient is considered CD38 þ if at least 40% of the CLL cells do express CD38 at detectable levels by flow cytometry.
d The percentage of dead CLL cells after 48 h of 10 mM 4HPR treatment is normalized to the spontaneous apoptosis in untreated cell cultures. The mean value of two (in some cases three) experiments is reported. experiencing 4HPR activity but still in a state that precedes their eventual death. Demonstration and description of this contention are provided in Supplemenatary Figure S3 and Supplementary Materials and methods.
As Mcl-1 expression analysis by flow cytometry (Figure 3b ) was performed selectively on cells within the 'live' gate, we may deduce that 4HPR triggered Mcl-1 downregulation before caspase3 was activated.
Further inspection of Mcl-1 in 'live' cells revealed that a substantial fraction of CLL cells displayed downregulated Mcl-1 already after 8-h 4HPR treatment, when DC dissipation and plasma-membrane permeability were absent or minimal (Figure 3e ). Caspase 3 inhibitors counteracted 4HPR-mediated apoptosis but did not affect Mcl-1 drop significantly (Figure 3e ). This confirmed that 4HPR-mediated decrease of Mcl-1 protein expression was an early event, not due to caspase degradation.
NF-kB, known to positively regulate Mcl-1, 28 is constitutively activated in CLL cells. 29 We examined the effects of 4HPR on NF-kB activity by western blot, because the antibody was not well suitable for flow cytometry. It has to be mentioned that protein expression evinced by the immunoblot technique arises from all CLL cells irrespective of their viability status, and may include proteins that are degraded by activated caspases. We found that the expression of phosphorylated RelA (p65), one of the major components of the active NF-kB complex, was decreased in CLL cells after treatment with 4HPR already after 24 h, when caspases were virtually not yet activated (Figure 3d ).
Previous work indicated that 4HPR promotes Mcl-1 downregulation through PKCdelta cleavage and activation. 30, 31 We addressed this issue in CLL cells and found that cleaved PKCdelta (the active catalytic subunit) is already expressed in untreated CLLs and 4HPR did not change expression levels of PKCdelta nor cleaved PKCdelta (Figure 3d) . Thus, PKCdelta appeared not to participate in 4HPR apoptosis or Mcl-1 downregulation in CLL cells.
Mcl-1 levels in ALL cells were reported to be reduced by 4HPR through activation of jun N-terminal kinase (JNK). 18 Expression of the active (phosphorylated) form of JNK in our CLL samples, evaluated by flow cytometry on cells in the 'live' gate, was increased in response to 4HPR (Figure 3e Mcl-1 is neutralized by one proapoptotic member of the Bcl-2 family, Noxa, which contributes to promote its proteasomal degradation. 33 Noxa protein expression was evaluated by flow cytometry on CLLs exposed to 4HPR and was found to be remarkably increased in response to 4HPR in all CLL samples analyzed (Figure 3f) .
Altogether, our data revealed that 4HPR cytotoxicity to CLL cells was associated with JNK-mediated decline of the antiapoptotic protein Mcl-1. Mcl-1 downregulation was not due to transcriptional inhibition or, at early stages, to caspase degradation. Correlated with Mcl-1 drop were a decreased activity of the transcription factor NF-kB and an augmented expression of the proapoptotic molecule Noxa.
4HPR sensitivity of CD40L-stimulated CLL cells is higher in activated/proliferating CLL cells than in activated/quiescent ones We examined whether 4HPR was effective on activated CLLs. CD40-expressing CLL samples were stimulated by CD40L fibroblasts and treated with 4HPR for 48 h. CD40L-stimulated CLLs underwent 4HPR-induced apoptosis (Figure 4a ), but the extent of apoptosis was lower compared with mock-stimulated CLLs (Figure 4b) . Thus, the activation partially protected CLL cells from apoptosis. The degree of protection differed from patient to patient, as indicated by its broad distribution in Figure 4c (left) ('Protection' parameter defined in Supplementary Materials and methods). To investigate whether 'protection' was related to the response to CD40L stimulation, we subdivided the 23 CLL patients into three subgroups: unresponsive (increase of activation markers CD40/CD69o50%), activated/resting (increase of CD40/ CD69450% and KI67 þ o15%) and activated/proliferating (KI67 þ 415%). According to the 'protection' levels examined separately for the three subgroups (Figure 4c, right) , we found that CD40L-responsive samples were partly protected from 4HPR cytotoxicity, but if they entered a proliferative status they almost recovered their basal 4HPR sensitivity (Figure 4c) .
We then compared the 4HPR sensitivity of proliferating cells with that of resting cells within the same CLL sample. Samples that proliferated in response to CD40L stimulation were stained for DNA content/KI67 expression and analyzed by flow cytometry. Cell death induced by 4HPR was more pronounced for the proliferating cell pool (for example, in Figure 4d : %KI67 þ decreased from 35 to 9%) than for the quiescent one (%KI67 À decreased from 65 to 41%) (Figure 4d ). The finding that 4HPR cytotoxicity was stronger in proliferating cells than in quiescent cells was confirmed in other eight CLL samples (Figure 4e ). After 48-h 4HPR treatment, the average CLL cell depauperation due to cell death was of 29% for quiescent cells and 72% for proliferating ones (Figure 4e ). These results, together with the observation that the extent of apoptosis in activated/proliferating samples was higher than in activated/resting ones, demonstrate that, in the presence of activation stimuli, proliferating cells are more susceptible to 4HPR than is the resting counterpart.
We examined whether Noxa was involved in this phenomenon. CLL samples were CD40L stimulated and treated with 4HPR for 48 h. Noxa expression was increased in some CLL samples simply by CD40L activation (Figure 4f ) and was further upregulated by 4HPR in most samples (Figure 4f ). Of the eleven CLL samples analyzed, five responded to the activation stimulus by entering active proliferation, whereas six exhibited activation markers but remained quiescent. We analyzed separately the two subgroups and found that proliferating samples displayed significantly higher Noxa elevation in response to both CD40L-stimulation and 4HPR treatment than the resting subgroup of CLLs (Figure 4f) .
Following these observations, we performed an intra-patient analysis. We selected the four most proliferating CLL samples and stained them with anti-Noxa/anti-KI67 antibodies. This allowed us to analyze separately, within the same sample, proliferating and quiescent cells. The results, shown in Figure 4g , indicated higher Noxa expression in cycling CLL cells compared with nonproliferating cells, already in untreated samples. 4HPR treatment further increased overall Noxa expression, resulting in a final Noxa level substantially higher in proliferating CLL cells than in quiescent cells (Figure 4g) .
Altogether, it appears that Noxa has a role in 4HPR-induced apoptosis of CLL cells, under both resting and microenvironmentstimulating conditions, and that the rise of Noxa observed in proliferating CLL cells after CD40L stimulation might partly contribute to counteracting the 4HPR-induced chemoresistance generally observed in activated CLL cells.
Combination cytotoxicity of 4HPR and fludarabine or ABT-737
We examined whether 4HPR modulates the in vitro cytotoxicity of the classical CLL drug F-ara-AMP. Analysis of five CLL samples demonstrated that, after 24 h, the combined treatment 4HPR þ F-ara-AMP induced higher cytotoxicity compared with each drug alone (Figure 5a ), in both resting and activated conditions. We then analyzed the cytotoxicity profiles of drugs alone or in combination at a constant 1:1 ratio and found an overall synergistic effect of the drug combination after 24-h treatment (Figure 5b) . We calculated the DRI in resting and activated CLL cells and found that 4HPR decreased the efficacious dose of F-ara-AMP by a factor of 2-7 ( Figure 5c ).
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Cytotoxicity of the BH3-only mimetic is affected by Mcl-1 activity. 35 We wondered whether 4HPR was able to increase ABT-737 potency in CLL cells. As ABT-737 alone was less effective on activated CLLs than on unstimulated ones, particularly when cells proliferated (average LC 50 ¼ 6.7 nM for unstimulated CLL cells and 4100 nM for CD40L-activated CLL cells) (data not shown), we used different concentrations of ABT-737 on resting or activated CLLs. As displayed in Figure 5d , co-administration of 4HPR for 24 h significantly increased the cytotoxicity of sub-lethal doses of ABT-737 (that is, 3 or 30 nM for resting or activated CLLs, respectively). CI values computed from cytotoxicity profiles demonstrated a good level of synergy in activated CLL samples, and less for resting ones, which displayed only an additive effect in two cases (Figure 5e) . DRI values were very variable, depending on the CLL patient and on its activation status. DRI ranged from 2 to 8 in resting CLL samples and were interestingly high in three out of five activated samples (B100 and above) (Figure 5f ). Of note, the three CLL samples displaying highest DRI values were the proliferating ones. Altogether, our data suggest that 4HPR vigorously potentiates the cytotoxic effects of ABT-737 in CD40L-stimulated CLL samples, with particular regard to proliferating CLL cells.
DISCUSSION
We documented the cytotoxic effects exerted by 4HPR in vitro on leukemic cells derived from previously untreated CLL patients (data summary in Supplementary Table S1 ). 4HPR elicited oxidative stress and activated the intrinsic apoptotic pathway. The cytotoxic activity of 4HPR was associated with Mcl-1 decline, which preceded mitochondrial membrane depolarization and caspase activation. The decline of Mcl-1 protein expression was not due to transcription inhibition, and was dependent on JNK activation. 4HPR indeed activated JNK in our CLL cells and this activation was involved in reduction of Mcl-1 protein expression. This mechanism was observed in ALL cells as well. 18 JNK activation facilitates Mcl-1 degradation by priming this protein for phosphorylation by GSK3, which in turn triggers Mcl-1 proteasomal degradation. 36 4HPR also upregulated Noxa protein expression in our CLL cells. Noxa is known to target Mcl-1 with high affinity 33 and promote its proteasomal degradation. 37 Altogether, we may postulate that proteasomal degradation is the main mechanism responsible for 4HPR-mediated Mcl-1 decrease.
NF-kB has an important role in survival and proliferation of CLL cells and is constitutively activated in these cells. 29 It positively regulates Mcl-1. 28 Its inhibition promoted CLL cell apoptosis. 38 We observed in our 4HPR-treated CLL cells remarkable downregulation of the active phosphorylated form of NF-kB. The PKC family of isoenzymes is composed of different members with a role in cell survival and malignant transformation. 39 The function of the delta isoform appears quite complex. Previous work, on cells other than CLLs, indicated that 4HPR promotes Mcl-1 downregulation through PKCdelta cleavage and activation. 30, 31 However, PKCdelta was already active in our untreated CLLs, in accordance with previous work demonstrating constitutive activation of PKCdelta in CLL cells 40, 41 and antiapoptotic, instead of death-promoting, activity in these cells. 41, 42 Altogether, different from other cell systems, in CLL cells PKCdelta appeared not to participate in 4HPR apoptosis or Mcl-1 downregulation.
4HPR sensitivity of resting CLL cells was partly reduced after leukemic cells became activated by CD40L stimulation, to an extent that depended on whether CLL activation was accompanied by cell cycling or not. Proliferating CLL cells were more prone to undergo 4HPR-induced apoptosis than activated, but resting, CLL cells, suggesting that 4HPR may represent a valuable support for the elimination of the in vivo cycling pool of leukemic cells in CLL disease.
4HPR displays good safety profiles. In vitro it exerts no, or very mild, cytotoxicity to normal cells 18, 19, 43 including B lymphocytes (Supplementary Figure S1) . In vivo, at plasma levels similar to the concentration active in vitro and utilized in this study, it is well tolerated. Steady-state plasma levels of 10 mM and above, achieved by standard 4HPR oral capsule (corn oil-based) administered during phase I/II trials on neuroblastoma and other pediatric solid tumors [44] [45] [46] and phase II on recurrent ovarian cancer, 47 were associated with modest and well-manageable systemic toxicity in adult patients 47 and even better tolerability in children. 45 Interestingly, novel 4HPR formulations with increased bioavailability compared with corn-oil capsules and currently in phase I display manifold increased 4HPR plasma levels. One promising formulation is a lipid matrix, LYM-X-SORB. 4HPR incorporated into it produced drug plasma levels of B10-20 mM and good safety profiles in pediatric patients with relapsed neuroblastoma 25 and adult patients with refractory solid tumors. 26 Another intralipid emulsion of 4HPR, ILE 4-HPR, resulted in safe steady-state plasma levels of 50-60 mM in pediatric patients with hematologic malignancies. 27 These novel drug delivery systems will lower the 4HPR dose required to achieve the consistent systemic exposures associated with activity in preclinical models.
ABT-737, and its orally active analog ABT-263 (Navitoclax), holds promise for the treatment of CLL disease. 48, 49 However, the cytotoxic activity of this BH3-only mimetic is impaired when Mcl-1 is overexpressed 35 and when cells are activated and proliferated (Vogler et al. 50 and our observation). These limiting features cannot be overcome by ABT-263 dose increase, owing to its known in vivo side effects that include thrombocytopenia 51 and, in some cases, severe thrombocytopathy. 52 In our study 4HPR potentiated significantly ABT-737 cytotoxicity, especially on dividing CLL samples, possibly because the ABT-737 chemoresistance of proliferating CLLs is well counterbalanced by 4HPR, which instead is more cytotoxic to actively cycling CLLs. Thus, 4HPR may facilitate the use of Navitoclax at lower concentrations, with a consequent decrease of treatment-derived morbidity. Likewise, 4HPR was capable of strongly potentiating the activity of fludarabine, in both resting and activated CLL cells.
Altogether, this study designates 4HPR as a promising chemotherapeutic adjuvant in CLL.
